{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:49:36Z","timestamp":1786121376249,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM121334"],"award-info":[{"award-number":["P20GM121334"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U54GM115428"],"award-info":[{"award-number":["5U54GM115428"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["0.174"],"award-info":[{"award-number":["0.174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["0.60"],"award-info":[{"award-number":["0.60"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["GOG-0213 phase-3"],"award-info":[{"award-number":["GOG-0213 phase-3"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["0.001"],"award-info":[{"award-number":["0.001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1.08"],"award-info":[{"award-number":["1.08"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006940","name":"University of Mississippi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006940","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.tranon.2020.100860","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:31:18Z","timestamp":1598574678000},"page":"100860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Candace M.","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim Bou","family":"Zgheib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Stephen","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"DeEulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth T.","family":"Lirette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagan","family":"Valluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Claudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2020.100860_bb0005","first-page":"323","article-title":"Medical therapy of advanced malignant epithelial tumours of the ovary","volume":"10","author":"Colombo","year":"2000","journal-title":"Forum (Genova)"},{"key":"10.1016\/j.tranon.2020.100860_bb0010","first-page":"627","article-title":"Current approach to epithelial ovarian cancer based on the concept of cancer stem cells","volume":"17","author":"Djordjevic","year":"2012","journal-title":"J Buon"},{"key":"10.1016\/j.tranon.2020.100860_bb0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/138920371604150429151457","article-title":"Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance","volume":"16","author":"Wang","year":"2015","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.tranon.2020.100860_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/cc.8.1.7533","article-title":"Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance","volume":"8","author":"Alvero","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.tranon.2020.100860_bb0025","article-title":"Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism","volume":"9","author":"Liao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100860_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029079","article-title":"Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer","volume":"7","author":"Vathipadiekal","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100860_bb0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/978-1-62703-547-7_25","article-title":"Ovarian cancer stem cells enrichment","volume":"1049","author":"Yang","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tranon.2020.100860_bb0040","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0045","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2020.100860_bb0050","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0055","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/IGC.0b013e3181f67418","article-title":"Primary chemotherapy: the future for the management of advanced ovarian cancer?","volume":"20","author":"Ledermann","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.tranon.2020.100860_bb0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3949\/ccjm.67.4.294","article-title":"The genetics, screening, and treatment of epithelial ovarian cancer: an update","volume":"67","author":"Markman","year":"2000","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.tranon.2020.100860_bb0065","article-title":"Recurrent epithelial ovarian cancer: an update on treatment","volume":"27","author":"Foley","year":"2013","journal-title":"Oncology (Williston Park)"},{"issue":"Suppl. 1","key":"10.1016\/j.tranon.2020.100860_bb0070","doi-asserted-by":"crossref","first-page":"i63","DOI":"10.1093\/annonc\/mdw079","article-title":"Recurrent ovarian cancer","volume":"27","author":"Pujade-Lauraine","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2020.100860_bb0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00404-009-1121-1","article-title":"Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas","volume":"281","author":"Matsuo","year":"2010","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.tranon.2020.100860_bb0085","series-title":"Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 2.2015","author":"NCCN","year":"2015"},{"key":"10.1016\/j.tranon.2020.100860_bb0090","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-012-2673-z","article-title":"Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation","volume":"20","author":"Fotopoulou","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0095","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0100","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0105","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0115","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0120","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdx010","article-title":"Fifth ovarian cancer consensus conference: individualized therapy and patient factors","volume":"28","author":"McGee","year":"2017","journal-title":"Ann. Oncol."},{"issue":"160","key":"10.1016\/j.tranon.2020.100860_bb0125","first-page":"e161","article-title":"Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer","volume":"203","author":"Havrilesky","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.tranon.2020.100860_bb0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2014.11.019","article-title":"A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer","volume":"136","author":"Plamadeala","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010035","article-title":"Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications","volume":"5","author":"Kelly","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100860_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105710","article-title":"Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors","volume":"9","author":"Mathis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100860_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijscr.2016.07.013","article-title":"A new complementary procedure for patients affected by head and neck cancer: chemo-predictive assay","volume":"26","author":"Cortese","year":"2016","journal-title":"Int. J. Surg. Case Rep."},{"key":"10.1016\/j.tranon.2020.100860_bb0150","first-page":"70","article-title":"Efficacy of ChemoID guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: case study","volume":"1","author":"DeEulis","year":"2017","journal-title":"Transl Med Rep"},{"key":"10.1016\/j.tranon.2020.100860_bb0155","doi-asserted-by":"crossref","unstructured":"Howard CM, Alberico A, Valluri J, Griswold M, Claudio PP: Analysis of chemo-predictive assay for targeting cancer stem cells in 41 glioblastoma patients. In J Clin Oncol, vol. 35. pp. (suppl; abstr e13544); 2017:(suppl; abstr e13544).","DOI":"10.1200\/JCO.2017.35.15_suppl.e13544"},{"key":"10.1016\/j.tranon.2020.100860_bb0160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tranon.2017.01.008","article-title":"Analysis of chemopredictive assay for targeting cancer stem cells in glioblastoma patients","volume":"10","author":"Howard","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0165","doi-asserted-by":"crossref","first-page":"100755","DOI":"10.1016\/j.tranon.2020.100755","article-title":"Cancer stem cell chemotherapeutics assay for prospective treatment of recurrent glioblastoma and progressive anaplastic glioma: a single-institution case series","volume":"13","author":"Ranjan","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0170","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1097\/SCS.0000000000001797","article-title":"A patient with a rare single mandibular localization of non-Hodgkin B-cell lymphoma: early differential diagnosis with dental lesions","volume":"26","author":"Cortese","year":"2015","journal-title":"J. Craniofac. Surg."},{"key":"10.1016\/j.tranon.2020.100860_bb0175","unstructured":"CMS Reimbursement Rates, Part B Drugs. Accessed April 3, 2020 [https:\/\/www.cms.gov\/apps\/ama\/license.asp?file=https%3A\/\/www.cms.gov\/files\/zip\/april-2020-asp-pricing-file.zip]."},{"key":"10.1016\/j.tranon.2020.100860_bb0180","unstructured":"CMS Physician Fee Schedule. Accessed April 5, 2020 [https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx]."},{"key":"10.1016\/j.tranon.2020.100860_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2007.06.029","article-title":"Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis","volume":"107","author":"Havrilesky","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0190","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature09781","article-title":"Cells of origin in cancer","volume":"469","author":"Visvader","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2020.100860_bb0195","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tranon.2020.100860_bb0200","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cr.2012.13","article-title":"Understanding cancer stem cell heterogeneity and plasticity","volume":"22","author":"Tang","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.tranon.2020.100860_bb0205","article-title":"Functional drug response assay for cancer stem cells in the era of precision medicine","volume":"1","author":"Howard","year":"2017","journal-title":"Translational Med. Rep."},{"key":"10.1016\/j.tranon.2020.100860_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcb.24317","article-title":"Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance","volume":"114","author":"Ahmed","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tranon.2020.100860_bb0215","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.mam.2013.06.002","article-title":"Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets","volume":"39","author":"Ahmed","year":"2014","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.tranon.2020.100860_bb0220","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","article-title":"Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer","volume":"65","author":"Bapat","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2020.100860_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.02.002","article-title":"Ovarian cancer stem cell markers: prognostic and therapeutic implications","volume":"322","author":"Burgos-Ojeda","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2020.100860_bb0230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.6004\/jnccn.2011.0009","article-title":"Point: chemosensitivity assays have a role in the management of recurrent ovarian cancer","volume":"9","author":"Schink","year":"2011","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"68","key":"10.1016\/j.tranon.2020.100860_bb0235","first-page":"e61","article-title":"Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer","volume":"203","author":"Herzog","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.tranon.2020.100860_bb0240","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/bjc.2014.375","article-title":"Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study","volume":"111","author":"Tian","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2020.100860_bb0245","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/CAD.0b013e3281de727e","article-title":"A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer","volume":"18","author":"Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S, Group TCAOCT","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.tranon.2020.100860_bb0250","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12094-014-1192-8","article-title":"Overview of a chemoresponse assay in ovarian cancer","volume":"16","author":"Grendys","year":"2014","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.tranon.2020.100860_bb0255","doi-asserted-by":"crossref","first-page":"12316","DOI":"10.18632\/oncotarget.24384","article-title":"Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs","volume":"9","author":"Haslem","year":"2018","journal-title":"Oncotarget"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320303521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320303521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:55:38Z","timestamp":1786074938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320303521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1936523320303521"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100860","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100860"}}